ITOC-2 is a European meeting intended to provide a platform for preclinical and clinical researchers in the field of immunotherapy. The concept is timely and necessary as agents have been licensed and arrived in clinical practice and many more similar drugs are expected to follow.

The goal of the Conference is to provide a forum for discussion of early clinical drug development and address its unique challenges of drug development.

The Conference will be of interest to representatives from academia, industry and other stakeholders who are involved in the development of novel anticancer agents.

The programme will focus on topics such as immunomodulatory agents, anti-cancer vaccines, adoptive and engineered T cell Therapy and monoclonal antibodies with special emphasis on translational research and biomarker development.